Semi-Annual Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7557806

Concept As at
2023-03-31
2022-04-01 to
2023-03-31
2021-04-01 to
2022-03-31
As at
2022-03-31
As at
2021-03-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
3,916,000,000 JPY
4,863,000,000 JPY
Interest and dividends received
337,000,000 JPY
292,000,000 JPY
Interest paid
-51,000,000 JPY
-58,000,000 JPY
Income taxes paid
-850,000,000 JPY
-1,385,000,000 JPY
Net cash provided by (used in) operating activities
3,351,000,000 JPY
2,842,000,000 JPY
Cash flows from investing activities
Purchase of securities
-400,000,000 JPY
JPY
Purchase of property, plant and equipment
-461,000,000 JPY
-579,000,000 JPY
Proceeds from sale of property, plant and equipment
0 JPY
10,312,000,000 JPY
Purchase of investment securities
JPY
-56,000,000 JPY
Proceeds from sale of investment securities
190,000,000 JPY
11,000,000 JPY
Other, net
-170,000,000 JPY
-1,091,000,000 JPY
Net cash provided by (used in) investing activities
-1,126,000,000 JPY
6,743,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-1,423,000,000 JPY
-2,298,000,000 JPY
Dividends paid
-452,000,000 JPY
-398,000,000 JPY
Net cash provided by (used in) financing activities
-1,820,000,000 JPY
-2,996,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
-2,000,000 JPY
0 JPY
Net increase (decrease) in cash and cash equivalents
402,000,000 JPY
6,589,000,000 JPY
Cash and cash equivalents
17,505,000,000 JPY
17,103,000,000 JPY
10,514,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.